Menu
Enrolling by invitation NCT06909929

High-Dose Intravenous Lipid for Very Preterm or Very Low Birth Weight Infants Effects on Growth

No phase Interventional Very Preterm Birth

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Lipid IV 2 g, lipid IV 1 gram.
Who it may be relevant to
Registry conditions: Very Preterm Birth. Basic parameters: up to 32 Weeks · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Indonesia
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

Pemberian Lipid Intravena Dosis Tinggi Untuk Bayi Sangat Prematur Atau Berat Lahir Sangat Rendah Terhadap Pertumbuhan

Overview

This is a RCT study conducted in Cipto Mangunkusumo Hospital in very preterm infants. The investigators compared early intravena lipid start with 2 gram per body weight and 1 gram per body weight and observed the time to reach birth weight.

Detailed description

Neonates with \<32 weeks gestation age or \<1500 gram birth weight gets early intravena lipid start with 2 gram per body weight and 1 gram per body weigh then observed the time to reach birth weight

Interventions

  • Dietary supplement Lipid IV 2 g
    This group will get 2 g of lipid IV in the early 24 hours of life
  • Dietary supplement lipid IV 1 gram
    This group will get 1 g of lipid IV in the early 24 hours of life

Primary outcome measures

  • return to birth weight [Time frame: day]

Eligibility criteria

Inclusion criteria

  • birth weight below 1500 gram or gestational age below 32 weeks

Exclusion criteria

  • mayor congenital abnormalities

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Single blind
Primary purpose
Supportive care

Study locations

Indonesia · 1 center
  • Cipto Mangunkusumo Hospital — Jakarta

Identifiers

NCT: NCT06909929 · LIPIP2GVS1G

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗